Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
RESEARCH TOOLSreports
Holding CYCN?
Track your performance easily
CYCN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.27 - $9.47
Previous Close$3.19
Volume269.56K
Average Volume (3M)3.07M
Market Cap
$7.99M
Enterprise Value$5.12M
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
May 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding2,710,096
10 Day Avg. Volume323,631
30 Day Avg. Volume3,066,641
Standard Deviation0.31
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.06
Price to Sales (P/S)39.97
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.61
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cyclerion Therapeutics News
PremiumCompany Announcements
Cyclerion Therapeutics Secures Funding and Expands CNS Focus
PremiumCompany Announcements
Cyclerion Therapeutics Appoints New CEO Regina Graul
Ownership Overview
17.63% Insiders
4.25% Mutual Funds
29.83% Other Institutional Investors
46.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CYCN FAQ
What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.27 and its highest was $9.47 in the past 12 months.
What is Cyclerion Therapeutics,Inc.’s market cap?
Currently, no data Available
When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
Cyclerion Therapeutics,Inc.’s upcoming earnings report date is May 01, 2024 which is 235 days ago.
How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
Cyclerion Therapeutics,Inc. released its earnings results on Feb 22, 2024. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.685.
Is Cyclerion Therapeutics,Inc. overvalued?
According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued.
Does Cyclerion Therapeutics,Inc. pay dividends?
Cyclerion Therapeutics,Inc. does not currently pay dividends.
What is Cyclerion Therapeutics,Inc.’s EPS estimate?
Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclerion Therapeutics,Inc. have?
Cyclerion Therapeutics,Inc. has 2,710,096 shares outstanding.
What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
Cyclerion Therapeutics,Inc. reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.42%.
Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
Among the largest hedge funds holding Cyclerion Therapeutics,Inc.’s share is Slate Path Capital LP. It holds Cyclerion Therapeutics,Inc.’s shares valued at 927K.
---
Cyclerion Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $554.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.94%
12-Months-Change
Fundamentals
Return on Equity
-50.13%
Trailing 12-Months
Asset Growth
-41.51%
Trailing 12-Months
Company Description
Cyclerion Therapeutics,Inc.
Cyclerion Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
---
Technical Analysis
---